Has Anil Trindade, MD received payments from drug or device companies?

Yes. Drug and device makers reported $11,331 in general payments to Anil Trindade, MD across 20 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Anil Trindade, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Anil Trindade, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Anil Trindade, MD

Pulmonary Disease · Nashville, TNNPI 1720132582

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Pulmonx Corporation at 34.0% of the total. 2025 is the largest year on record at $7,315, more than ten times the $130 reported in 2022.

$11,331in general payments, 2019–2025

Across 20 payments — averaging $566.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pulmonx Corporation$4K
Zambon USA Ltd.$4K
United Therapeutics Corporation$3K
Polarean, Inc.$344
Takeda Pharmaceuticals U.S.A., Inc.$210
Kamada Ltd.$80
plus $70 from 1 others

$177,902in research payments, 2019–2025

Across 46 payments — averaging $3867.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sanofi US Services Inc.$120K
Veloxis Pharmaceuticals, Inc.$30K
United Therapeutics Corporation$18K
Xvivo Perfusion Inc.$10K
Sanofi-aventis U.S. LLC$90

What the payments were for

Consulting fees$5,82051%
Speaking & faculty fees$3,39030%
Travel & lodging$4944%
Food & beverage$1,62714%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pulmonx Corporation	4	$3,849
Zambon USA Ltd.	6	$3,834
United Therapeutics Corporation	5	$2,944
Polarean, Inc.	1	$344
Takeda Pharmaceuticals U.S.A., Inc.	2	$210
Kamada Ltd.	1	$80
Veloxis Pharmaceuticals, Inc.	1	$70

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,331 in reported general payments places this provider in the 75th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee →

Medicare billing

Part B allowed, 2024

$46,845

Medicare patients

157

Services billed

541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
LokelmaSodium Zirconium Cyclosilicate	11	$18,091
Tacrolimus	45	$11,129
ArexvyRsvpref3 Antigen/As01e/Pf	17	$4,466
Valganciclovir Hcl	11	$2,481
Mycophenolate Mofetil	20	$2,269
Azithromycin	145	$2,114
Dapsone	17	$1,247
Famotidine	57	$858
ValacyclovirValacyclovir Hcl	11	$735
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	141	$700
Mirtazapine	17	$627
Prednisone	89	$600
Nifedipine ErNifedipine	16	$594
Losartan Potassium	67	$559
Gabapentin	47	$532

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Nashville

Lisa LancasterNashville$519K
Otis RickmanNashville$392K
Susan GarwoodNashville$343K
Joao DeandradeNashville$245K
Anna HemnesNashville$183K
Bryan HayNashville$126K
Karl KuhnNashville$106K
Fabien MaldonadoNashville$83K
Margaret SalisburyNashville$53K
Victor KhaNashville$44K

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →